Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Wang W, Bai W, Wang E, Zhao Y, et al. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. Int J Cancer 2017;140:390-399.
PMID: 27681592


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016